Social anxiety disorder

VistaGen to Participate in Upcoming June Investor Conferences

Retrieved on: 
Friday, May 27, 2022
Mental Health, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Central nervous system disease, FDA, Neuron, CNS, Therapy, Brain, Company, PH94B, Social anxiety disorder, Anxiety, Nasdaq, Depression, Pharmaceutical industry, Baking

VistaGen (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders.

Key Points: 
  • VistaGen (Nasdaq: VTGN) is a late clinical-stage, CNS-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders.
  • The Company is advancing first-in-class therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available.
  • VistaGens clinical-stage candidates are targeting multiple forms of anxiety and depression.
  • VistaGens lead candidate, PH94B, is a nasally administered spray currently in multiple Phase 3 trials in the U.S., with results anticipated in 2022.

World Social Anxiety Disorder (SAD) Epidemiology Forecast/Analysis Report 2022-2032 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 20, 2022
Other Consumer, Other Health, Health, General Health, Women, Men, Mental Health, Research, Consumer, Science, Teens, Disease, Epidemiology, Social anxiety disorder, SAD, United Kingdom, Diagnosis, Classification, Table, Meat, Dentistry

This "Social Anxiety Disorder (SAD) - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Social Anxiety Disorder (SAD) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Key Points: 
  • This "Social Anxiety Disorder (SAD) - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Social Anxiety Disorder (SAD) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • The Social Anxiety Disorder (SAD) epidemiology report gives a thorough understanding of the Social Anxiety Disorder (SAD) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis.
  • The Social Anxiety Disorder (SAD) epidemiology covered in the report provides historical as well as forecasted Social Anxiety Disorder (SAD) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
  • The Social Anxiety Disorder (SAD) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
    The Social Anxiety Disorder (SAD) Epidemiology Report and Model provide an overview of the global trends of Social Anxiety Disorder (SAD) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
    The report provides insight into the historical and forecasted patient pool of Social Anxiety Disorder (SAD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan

Global Social Anxiety Disorder Drugs Development Pipeline Report 2022: Stages, Target, MoA, RoA, Molecule Type and Key Players - ResearchAndMarkets.com

Retrieved on: 
Friday, May 20, 2022
Pharmaceutical, Health, Mental Health, Molecule, History, R, Social anxiety disorder, News, Route of administration, Mall of America, Decision-making, Research, Key, Social anxiety, Therapy, Administration, Target, Pharmaceutical industry

The "Social Anxiety Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Social Anxiety Disorder Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players" report has been added to ResearchAndMarkets.com's offering.
  • Social Anxiety Disorder (SAD/Social Phobia) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players provides an overview of the Social Anxiety Disorder (SAD/Social Phobia) pipeline landscape.
  • The report provides comprehensive information on the therapeutics under development for Social Anxiety Disorder (SAD/Social Phobia), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.
  • Additionally, the report provides an overview of key players involved in therapeutic development and features dormant and discontinued projects.

VistaGen Announces Key Regulatory Update on PH94B for the Acute Treatment of Social Anxiety Disorder

Retrieved on: 
Thursday, May 5, 2022
Mental Health, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, COVID-19, Fear, Brain, Decision-making, U.S. Securities and Exchange Commission, Nasdaq, CNS, Company, Panic disorder, Food, HAP, Depression, MOA, Central nervous system disease, Patient, Neuron, GABA, Animal, Risk, FDA, Annual report, Therapy, Anxiety, Industry, Dopamine, Benzodiazepine, Fast Track, Marketing, Regulation of tobacco by the U.S. Food and Drug Administration, PTSD, Social anxiety disorder, SEC, PALISADE, SAD, Central nervous system, Pharmaceutical industry, PH94B

VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a late clinical-stage, central nervous system (CNS) focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders, announced today a key regulatory update on its PALISADE Phase 3 Program for PH94B for the acute treatment of anxiety in adults with social anxiety disorder (SAD).

Key Points: 
  • VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a late clinical-stage, central nervous system (CNS) focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other CNS disorders, announced today a key regulatory update on its PALISADE Phase 3 Program for PH94B for the acute treatment of anxiety in adults with social anxiety disorder (SAD).
  • Based on positive Phase 2 data in social anxiety disorder (SAD) patients, VistaGen is currently evaluating PH94B in two Phase 3 clinical studies in the U.S., PALISADE-1 and PALISADE-2, and a long-term safety study, for the acute treatment of anxiety in adults with SAD.
  • In addition to SAD, for which the FDA has granted Fast Track designation, PH94B has potential in adjustment disorder with anxiety, procedural anxiety, PTSD, postpartum anxiety and panic disorder.
  • Should ongoing Phase 3 studies be successful, PH94B has the potential to be the first FDA-approved, fast-acting, acute treatment of anxiety for adults with social anxiety disorder.

VistaGen Appoints Reid Adler as Chief Legal Officer

Retrieved on: 
Monday, May 2, 2022
Legal, Mental Health, Research, Clinical Trials, Professional Services, Biotechnology, Health, Pharmaceutical, Science, Transfer, Technology transfer, Board, Strategic planning, Board of directors, University, Brain, Nasdaq, University of Maryland, College Park, College Park, CNS, Company, Mixed anxiety–depressive disorder, NIH, Adler, Depression, Â, PH94B, Central nervous system disease, Patient, Neuron, Organization, FDA, Coalition for Epidemic Preparedness Innovations, Coalition, Therapy, Anxiety, National, Epidemic, Genomics, Vaccine, Hotel manager, Bachelor of Science in Human Biology, George Washington University, Social anxiety disorder, J. Craig Venter Institute, NIH Office of Technology Transfer, Technology, Research, Morrison & Foerster, Central nervous system, Management, Medicine, Pharmaceutical industry

VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen) a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, today announced the appointment of Reid Adler as its Chief Legal Officer.

Key Points: 
  • VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen) a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, today announced the appointment of Reid Adler as its Chief Legal Officer.
  • Adler will oversee VistaGen's legal affairs and provide strategic guidance to its Executive Team and Board of Directors.
  • We are excited to welcome Reid to VistaGens Executive Team, said Shawn Singh, Chief Executive Officer .
  • It's a privilege to join the VistaGen leadership team after supporting the companys efforts as outside counsel, stated Reid Adler.

VistaGen to Present Preclinical Data on Lead Candidate PH94B at Upcoming Scientific Congresses

Retrieved on: 
Thursday, April 21, 2022
Mental Health, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, PH94B, Society, ASCP, SAD, U.S. Securities and Exchange Commission, Marketing, Annual general meeting, COVID-19, MOA, Brain, Anxiety, Neuron, Annual report, Translational medicine, CNS, Central nervous system, Risk, Patient, Nasdaq, Company, Laboratory, Depression, SEC, Social anxiety disorder, Fast Track, Central nervous system disease, Major depressive disorder, Benzodiazepine, FDA, Industry, Biological Psychiatry (journal), PALISADE, Therapy, Pharmaceutical industry

VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen) a late clinical-stage, central nervous system (CNS) focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, announced that researchers will present preclinical data supporting the differentiated mechanism of action (MOA) for VistaGens lead product candidate, PH94B, at two upcoming major scientific congresses.

Key Points: 
  • VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen) a late clinical-stage, central nervous system (CNS) focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, announced that researchers will present preclinical data supporting the differentiated mechanism of action (MOA) for VistaGens lead product candidate, PH94B, at two upcoming major scientific congresses.
  • VistaGen is currently evaluating PH94B in multiple Phase 3 trials for the acute treatment of anxiety in adults with social anxiety disorder (SAD).
  • VistaGen is committed to transforming the existing standards of treatments for anxiety and depression disorders, said Shawn Singh, Chief Executive Officer of VistaGen .
  • As these preclinical data demonstrate, the proposed mechanism of action of our Phase 3 clinical candidate, PH94B, is fundamentally unique from all currently available anti-anxiety therapies.

VistaGen and AffaMed Complete Key Regulatory Submissions for PALISADE Global Phase 3 Clinical Trial for PH94B

Retrieved on: 
Tuesday, April 12, 2022
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, PH94B, NDA, Social anxiety disorder, COVID-19, MOA, NMPA, CNS, Central nervous system, Risk, Columbia University, Patient, BMC Medicine, Central nervous system disease, Neuro, Multimedia, FDA, Benzodiazepine, Anxiety disorder, Therapy, CTA, Wellness, IND, Annual report, Anxiety, Food, Mental health, World Mental Health survey initiative, Company, National Medical Products Administration, Marketing, Kantar Health, BMC, National, Nasdaq, LSAS, Depression, SEC, Safety, Fast Track, Industry, SAD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Neuron, Liebowitz social anxiety scale, Brain, Frost & Sullivan, National Health, Pharmaceutical industry

NMPAs clearance to begin the PALISADE Global Phase 3 trial is a tremendous milestone in advancing our product portfolio targeting neurological and psychiatric indications.

Key Points: 
  • NMPAs clearance to begin the PALISADE Global Phase 3 trial is a tremendous milestone in advancing our product portfolio targeting neurological and psychiatric indications.
  • We thank the NMPA for recognizing the importance of this Phase 3 study and rapidly expediting the approval of our CTA.
  • VistaGen and AffaMed plan to begin enrolling participants in PALISADE Global during the second half of 2022, with topline results anticipated in mid-2024.
  • Separate from PALISADE Global, VistaGen is currently evaluating PH94B in Phase 3 clinical studies and a long-term safety study that, if successful, will support VistaGens PH94B NDA submission to the FDA.

Wise Therapeutics Announces Healthcare Provider Integrated Deployments to Serve Critical Need for More Accessible Mental Health Treatments

Retrieved on: 
Wednesday, April 6, 2022
Social anxiety disorder, Therapy, PDT, Mental health, Clinical trial, Research, CEO, Prescription, Entrepreneurship, Generalized anxiety disorder, United States Public Health Service, Policy, HYM, FDA, Patient, Pharmaceutical industry

NEW YORK, April 6, 2022 /PRNewswire/ -- Wise Therapeutics (Wise), a leading developer of game-based digital therapeutics for mental health, announced new deployments of their digital therapeutics across a variety of healthcare settings, ranging from therapy practices to large health systems. These deployments were enabled by the launch of their clinically integrated provider deployment platform, Wise Connect™.

Key Points: 
  • NEW YORK, April 6, 2022 /PRNewswire/ -- Wise Therapeutics (Wise), a leading developer of game-based digital therapeutics for mental health, announced new deployments of their digital therapeutics across a variety of healthcare settings, ranging from therapy practices to large health systems.
  • These deployments were enabled by the launch of their clinically integrated provider deployment platform, Wise Connect.
  • Wise is working towards FDA clearance of these PDTs as validated mental health treatments that require provider prescriptions.
  • Wise Therapeutics combines clinical neuroscience with mobile gaming to develop engaging, clinically validated digital therapeutics that address pervasive mental health challenges.

VistaGen to Participate in Fireside Chat at Maxim Group 2022 Virtual Growth Conference

Retrieved on: 
Thursday, March 24, 2022
Maxim, Company, Therapy, Marketing, Neuro, Central nervous system, CNS, Risk, SEC, Social anxiety disorder, Conference, PH94B, Industry, U.S. Securities and Exchange Commission, Nasdaq, COVID-19, Brain, GLOBE, Neuron, Anxiety, Central nervous system disease, SAN, Depression, FDA, Annual report, Pharmaceutical industry

In addition to his fireside chat, Mr. Singh will provide a recorded corporate presentation, available on demand to all registered conference attendees, during which he will highlight VistaGens pipeline, recent achievements, and anticipated milestones.

Key Points: 
  • In addition to his fireside chat, Mr. Singh will provide a recorded corporate presentation, available on demand to all registered conference attendees, during which he will highlight VistaGens pipeline, recent achievements, and anticipated milestones.
  • A link to the recorded presentation may be found on the Events page within the Investors section of the VistaGen website , beginning Monday, March 28, 2022, at 6:00 a.m. Pacific Time.
  • VistaGen (Nasdaq: VTGN) is a late clinical-stage, neuro-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders.
  • Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by VistaGen and its management, are inherently uncertain.

Receptor Life Sciences Announces FDA Acceptance of IND Application for RLS103 (Inhaled Dry Powder CBD) and Initiation of IND-Opening Clinical Safety and Efficacy Study

Retrieved on: 
Wednesday, March 30, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Journal, Pharmacy, Anxiety, Lists of Palestinian rocket attacks on Israel, Absorption, Trial of the century, European Journal of Pharmaceutical Sciences, IND, Mental health, Social anxiety disorder, Observation, National Institute of Mental Health, National Institute, CEO, Food, Anxiety disorder, Drug discovery, Safety, Social anxiety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, RLS, List of life sciences, Inhalation, FDA, Panic disorder, Patient, Neurological disorder, Pharmaceutical industry, CBD

RLS103, a dry powder inhaled cannabidiol (CBD), is a first-in-class drug/device combination product for the acute treatment of social anxiety disorder.

Key Points: 
  • RLS103, a dry powder inhaled cannabidiol (CBD), is a first-in-class drug/device combination product for the acute treatment of social anxiety disorder.
  • RLS is initiating a proof-of-concept Phase 1b clinical safety and efficacy study in social anxiety disorder.
  • The results will be used to facilitate the design of a larger, well-controlled, randomized Phase 2/3 safety and efficacy study intended for registration.
  • This IND acceptance allows us to test RLS103 in a number of clinical proof-of-concept safety and efficacy studies.